Molekulargenetisches Labor
Zentrum für Nephrologie und Stoffwechsel

Einwärts gerichteter Kalium-Kanal, Subfamilie J, Typ 11

Das Protein, welches von diesem Gen kodiert wird, ist ein Kaliumkanal, der für die Steuerung der Insulinsekretion in den pankreatischen Betazellen verantwortlich ist. Bei loss-of-function Mutationen kommt es zu einer autosomal rezessiven oder seltener dominanten hyperinsulinämischen Hypoklykämie. Dagegen führen aktivitätssteigernde Mutationen zu einem autosomal dominantem permanenten neonatalen oder jugendlichen (MODY13) Diabetes mellitus, der gelegentlich mit neurologischen Symptomen vergesellschaftet sein kann und dann als DEND-Syndrom bezeichnet wird.

Gentests:

Klinisch Untersuchungsmethoden Familienuntersuchung
Bearbeitungszeit 5 Tage
Probentyp genomische DNS
Klinisch Untersuchungsmethoden Hochdurchsatz-Sequenzierung
Bearbeitungszeit 25 Tage
Probentyp genomische DNS
Klinisch Untersuchungsmethoden Direkte Sequenzierung der proteinkodierenden Bereiche eines Gens
Bearbeitungszeit 20 Tage
Probentyp genomische DNS
Klinisch Untersuchungsmethoden Multiplex ligationsabhängige Amplifikation
Bearbeitungszeit 25 Tage
Probentyp genomische DNS

Verknüpfte Erkrankungen:

Hyperinsulinämische Hypoglycämie 2
KCNJ11
Permanenter neonataler Diabetes mellitus
ABCC8
DEND-Syndrom
KCNJ11
GCK
INS
KCNJ11
Phosphoribosylpyrophosphat-Synthetase-Überaktivität
PRPS1
Wolcott-Rallison-Syndrom
EIF2AK3
Transienter neonataler Diabetes mellitus 3
KCNJ11
DEND-Syndrom
KCNJ11
MODY13 Diabetes
KCNJ11

Referenzen:

1.

Tornovsky S et al. (2004) Hyperinsulinism of infancy: novel ABCC8 and KCNJ11 mutations and evidence for additional locus heterogeneity.

[^]
2.

Thomas PM et al. (1995) Homozygosity mapping, to chromosome 11p, of the gene for familial persistent hyperinsulinemic hypoglycemia of infancy.

[^]
3.

Hansen SK et al. (2005) Analysis of separate and combined effects of common variation in KCNJ11 and PPARG on risk of type 2 diabetes.

[^]
4.

et al. (2007) Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels.

[^]
5.

Scott LJ et al. (2007) A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants.

[^]
6.

Zeggini E et al. (2007) Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes.

[^]
7.

Gloyn AL et al. (2004) Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes.

[^]
8.

Massa O et al. (2005) KCNJ11 activating mutations in Italian patients with permanent neonatal diabetes.

[^]
9.

Proks P et al. (2005) A gating mutation at the internal mouth of the Kir6.2 pore is associated with DEND syndrome.

[^]
10.

Gloyn AL et al. (2006) KCNJ11 activating mutations are associated with developmental delay, epilepsy and neonatal diabetes syndrome and other neurological features.

[^]
11.

Masia R et al. (2007) An ATP-binding mutation (G334D) in KCNJ11 is associated with a sulfonylurea-insensitive form of developmental delay, epilepsy, and neonatal diabetes.

[^]
12.

Shimomura K et al. (2007) A novel mutation causing DEND syndrome: a treatable channelopathy of pancreas and brain.

[^]
13.

Sumnik Z et al. (2007) Sulphonylurea treatment does not improve psychomotor development in children with KCNJ11 mutations causing permanent neonatal diabetes mellitus accompanied by developmental delay and epilepsy (DEND syndrome).

[^]
14.

Mlynarski W et al. (2007) Sulfonylurea improves CNS function in a case of intermediate DEND syndrome caused by a mutation in KCNJ11.

[^]
15.

Koster JC et al. (2008) The G53D mutation in Kir6.2 (KCNJ11) is associated with neonatal diabetes and motor dysfunction in adulthood that is improved with sulfonylurea therapy.

[^]
16.

Slingerland AS et al. (2008) Sulphonylurea therapy improves cognition in a patient with the V59M KCNJ11 mutation.

[^]
17.

Koster JC et al. (2008) DEND mutation in Kir6.2 (KCNJ11) reveals a flexible N-terminal region critical for ATP-sensing of the KATP channel.

[^]
18.

Della Manna T et al. (2008) Glibenclamide unresponsiveness in a Brazilian child with permanent neonatal diabetes mellitus and DEND syndrome due to a C166Y mutation in KCNJ11 (Kir6.2) gene.

[^]
19.

Mohamadi A et al. (2010) Medical and developmental impact of transition from subcutaneous insulin to oral glyburide in a 15-yr-old boy with neonatal diabetes mellitus and intermediate DEND syndrome: extending the age of KCNJ11 mutation testing in neonatal DM.

[^]
20.

Henwood MJ et al. (2005) Genotype-phenotype correlations in children with congenital hyperinsulinism due to recessive mutations of the adenosine triphosphate-sensitive potassium channel genes.

[^]
21.

Pinney SE et al. (2008) Clinical characteristics and biochemical mechanisms of congenital hyperinsulinism associated with dominant KATP channel mutations.

[^]
22.

de Lonlay P et al. (1997) Somatic deletion of the imprinted 11p15 region in sporadic persistent hyperinsulinemic hypoglycemia of infancy is specific of focal adenomatous hyperplasia and endorses partial pancreatectomy.

[^]
23.

Marthinet E et al. (2005) Severe congenital hyperinsulinism caused by a mutation in the Kir6.2 subunit of the adenosine triphosphate-sensitive potassium channel impairing trafficking and function.

[^]
24.

Taneja TK et al. (2009) Sar1-GTPase-dependent ER exit of KATP channels revealed by a mutation causing congenital hyperinsulinism.

[^]
25.

Thomas P et al. (1996) Mutation of the pancreatic islet inward rectifier Kir6.2 also leads to familial persistent hyperinsulinemic hypoglycemia of infancy.

[^]
26.

Nestorowicz A et al. (1997) A nonsense mutation in the inward rectifier potassium channel gene, Kir6.2, is associated with familial hyperinsulinism.

[^]
27.

Inagaki N et al. (1995) Reconstitution of IKATP: an inward rectifier subunit plus the sulfonylurea receptor.

[^]
28.

Laukkanen O et al. (2004) Polymorphisms of the SUR1 (ABCC8) and Kir6.2 (KCNJ11) genes predict the conversion from impaired glucose tolerance to type 2 diabetes. The Finnish Diabetes Prevention Study.

[^]
29.

Yorifuji T et al. (2005) The C42R mutation in the Kir6.2 (KCNJ11) gene as a cause of transient neonatal diabetes, childhood diabetes, or later-onset, apparently type 2 diabetes mellitus.

[^]
30.

Gloyn AL et al. (2005) Relapsing diabetes can result from moderately activating mutations in KCNJ11.

[^]
31.

Colombo C et al. (2005) Transient neonatal diabetes mellitus is associated with a recurrent (R201H) KCNJ11 (KIR6.2) mutation.

[^]
32.

Koster JC et al. (2000) Targeted overactivity of beta cell K(ATP) channels induces profound neonatal diabetes.

[^]
33.

Yamada K et al. (2001) Protective role of ATP-sensitive potassium channels in hypoxia-induced generalized seizure.

[^]
34.

Ribalet B et al. (2003) Molecular basis for Kir6.2 channel inhibition by adenine nucleotides.

[^]
35.

Gloyn AL et al. (2004) Permanent neonatal diabetes due to paternal germline mosaicism for an activating mutation of the KCNJ11 Gene encoding the Kir6.2 subunit of the beta-cell potassium adenosine triphosphate channel.

[^]
36.

Proks P et al. (2004) Molecular basis of Kir6.2 mutations associated with neonatal diabetes or neonatal diabetes plus neurological features.

[^]
37.

Gupta RK et al. (2005) The MODY1 gene HNF-4alpha regulates selected genes involved in insulin secretion.

[^]
38.

Proks P et al. (2005) Functional effects of KCNJ11 mutations causing neonatal diabetes: enhanced activation by MgATP.

[^]
39.

Gloyn AL et al. (2006) Mutations in the genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) in diabetes mellitus and hyperinsulinism.

[^]
40.

Slingerland AS et al. (2006) Activating mutations in the gene encoding Kir6.2 alter fetal and postnatal growth and also cause neonatal diabetes.

[^]
41.

Lin YW et al. (2008) Destabilization of ATP-sensitive potassium channel activity by novel KCNJ11 mutations identified in congenital hyperinsulinism.

[^]
42.

Girard CA et al. (2009) Expression of an activating mutation in the gene encoding the KATP channel subunit Kir6.2 in mouse pancreatic beta cells recapitulates neonatal diabetes.

[^]
43.

Clark RH et al. (2010) Muscle dysfunction caused by a KATP channel mutation in neonatal diabetes is neuronal in origin.

[^]
44.

Chandy KG et al. (1993) Nomenclature for mammalian potassium channel genes.

[^]
45.

Inagaki N et al. (1996) A family of sulfonylurea receptors determines the pharmacological properties of ATP-sensitive K+ channels.

[^]
46.

Miki T et al. (1997) Abnormalities of pancreatic islets by targeted expression of a dominant-negative KATP channel.

[^]
47.

Hani EH et al. (1998) Missense mutations in the pancreatic islet beta cell inwardly rectifying K+ channel gene (KIR6.2/BIR): a meta-analysis suggests a role in the polygenic basis of Type II diabetes mellitus in Caucasians.

[^]
48.

NCBI article

NCBI 3767 [^]
49.

OMIM.ORG article

Omim 600937 [^]
50.

Orphanet article

Orphanet ID 122787 [^]
Update: 29. April 2019